Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash & Current Investments: 2010-2025

Historic Cash & Current Investments for Sunshine Biopharma (SBFM) over the last 13 years, with Sep 2025 value amounting to $9.3 million.

  • Sunshine Biopharma's Cash & Current Investments fell 23.76% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.5 million, marking a year-over-year decrease of 34.73%. This contributed to the annual value of $9.7 million for FY2024, which is 40.55% down from last year.
  • Sunshine Biopharma's Cash & Current Investments amounted to $9.3 million in Q3 2025, which was down 9.69% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Cash & Current Investments ranged from a high of $41.7 million in Q2 2022 and a low of $1.7 million during Q2 2021.
  • Moreover, its 3-year median value for Cash & Current Investments was $12.2 million (2024), whereas its average is $13.9 million.
  • Per our database at Business Quant, Sunshine Biopharma's Cash & Current Investments spiked by 9,706.42% in 2021 and then slumped by 53.54% in 2023.
  • Sunshine Biopharma's Cash & Current Investments (Quarterly) stood at $2.1 million in 2021, then spiked by 963.27% to $21.8 million in 2022, then dropped by 25.35% to $16.3 million in 2023, then plummeted by 40.55% to $9.7 million in 2024, then decreased by 23.76% to $9.3 million in 2025.
  • Its Cash & Current Investments stands at $9.3 million for Q3 2025, versus $10.3 million for Q2 2025 and $8.2 million for Q1 2025.